•
Jun 30, 2024
Cytokinetics Q2 2024 Earnings Report
Cytokinetics reported financial results for Q2 2024 and provided a management update.
Key Takeaways
Cytokinetics reported a net loss of $143.3 million for the second quarter of 2024. The company had $1.4 billion in cash, cash equivalents and investments as of June 30, 2024.
Held Type B meeting with FDA regarding risk mitigation strategies for aficamten.
Initiated rolling NDA submission for aficamten.
FDA cleared protocol amendment for FOREST-HCM, reducing echocardiographic monitoring frequency.
Cash, cash equivalents, and investments totaled ~$1.4 billion as of June 30, 2024.
Cytokinetics
Cytokinetics
Forward Guidance
The company updated its full year 2024 financial guidance.